North America Autoimmune Disease Diagnostics Market

Market Overview

Autoimmune illnesses are also characterized by the activation of self-reactive T cells, the production of autoantibodies, and inflammation. Immune cells may recognize foreign substances such as bacteria and viruses and send out fighter cells to combat them. The immune system is forced to combat itself in autoimmune illnesses.

But in certain cases, the immune system misidentifies parts of your body, such as your joints or skin, as an alien in an autoimmune disease. Autoantibodies are proteins released by the body that assault healthy cells. Some autoimmune disorders are limited to a single organ. The pancreas is harmed by type 1 diabetes. Systemic lupus erythematosus (SLE), for example, affects the entire body. These are non-communicable conditions in which the immune system loses its natural balance. This organism is in charge of causing an abnormal response in its tissue cells.

In 2021, the global autoimmune disease diagnostics market was worth USD 4,253.29 million, and by 2030, it is expected to be worth USD 8089.97 million. During the forecast period (2022–2030), the market is expected to develop at a CAGR of 7.17%. The North American market is the largest one and is expected to be valued at USD 3269 million by 2030 and its CAGR for the period of 2022-2030 is expected to be 7.48% keeping 2021 as the base year.

Market Dynamics

North America Autoimmune Disease Diagnostics Market Drivers

Increasing public awareness and the incidence of autoimmune disorders are likely to raise the market size for autoimmune disease testing in the coming years. According to the National Stem Cell Foundation, around 4% of the world's population is affected by one of the more than 800 autoimmune variations. Crohn's disease, scleroderma, psoriasis, Type 1 diabetes, and lupus are among the most frequent disorders.

Market expansion will be aided by significant players' focus on releasing new goods and implementing broader growth strategies. Increased partnerships, collaborations, and joint ventures will propel the market even further forward. The American Kidney Fund (AFK) began a public awareness campaign for lupus nephritis, a kidney condition caused by lupus, in February 2021. This campaign attempts to educate people on the symptoms, signs, and treatment of lupus nephritis. GSK, a major player in the market, helped the effort by providing a substantial gift.

The American Autoimmune Related Diseases Association (AARDA) and other organizations strive to raise awareness about autoimmunity's socio-economic impact by fostering and facilitating collaboration in the areas of education, public awareness, research, and patient services in a way that is effective, ethical, and efficient. Other market drivers include better laboratory automation, partnerships with physicians and clinical laboratories, technology improvements, and the Patient Protection and Affordable Care Act's expansion of coverage.

Because of the rising prevalence of autoimmune illness among the population, the US market is expected to drive the significant deployment of these diagnostic tests such as ANA blood tests over the projected period. According to the National Institute of Health, approximately 23.5 million Americans were diagnosed with an autoimmune disease in 2017, with the number expected to rise dramatically in the coming years.

Consequently, government strategies and plans addressing the burden of autoimmune disorders have been essential in driving demand for these diagnostic tests across North America. In certain cases, Autoimmune Diseases are even protected under the ‘Americans With Disability Act.

North America Autoimmune Disease Diagnostics Market Restraints

The market for autoimmune disease diagnostics has been declining as in-patient visits to hospitals, clinics, and laboratories have decreased. As the pandemic progressed, the market picked up speed due to the relaxation of lockdown measures and increased mobility among the general public.

The severity of the virus lowers TSH and TT3 levels, according to a study titled "Thyroid Function Analysis in 50 Patients with COVID-19: A Retrospective Study." In terms of management and further relief, the National Psoriasis Foundation (NPF) gathered and distributed vital information for healthcare providers and individuals living with psoriatic illness. Trade practices were suspended globally as countries instituted lockdowns during the ongoing outbreak. Furthermore, regional and worldwide travel restrictions were imposed, forcing the majority of the population to return home.

Moreover, to offer a complete picture, multiple laboratory tests are required. A complete metabolic panel, blood count report, serologies, flow cytometry, and HLA typing are just a few of the tests available. Some tests are used to diagnose and manage patients and are only beneficial for determining the severity and intensity of the condition.

North America Autoimmune Disease Diagnostics Market Opportunities

The Autoimmune Disease Diagnostics Market in North America is competitive. Major market players are focused on R&D efforts and significant growth strategies in this industry. A few diagnostic businesses have recently formed strategic alliances with hospitals. This tendency is projected to continue in the next few years in order to accommodate the huge volume of patient demands in various regions.

The growing public awareness of autoimmune disorders provides fertile ground for the development of novel and accurate diagnostic tools. The automation of laboratories and the rising shift toward replacing traditional technologies are predicted to pave the way for a larger global autoimmune disease diagnostics market.

Recent Developments

• Exagen Inc. announced the launch of AVISE CTD and AVISE Lupus, a contracted covered service with Inland Empire Health Plan, in October 2021. (IEHP). It serves around 1.4 million members with enhanced care.
• Exagen Inc. stated in January 2021 that Tufts Medical Centre had contracted in-network coverage for all AVISE test options (SLE Monitor, CTD, APS, Lupus, MTX, SLE Prognostic, Vasculitis AAV, MTX, and HCQ).